This dataset provides within-arm results for dichotomous outcomes: loss of diagnosis and clinically meaningful response. Included is information on how loss of diagnosis and clinically meaningful response were defined as well as the percent of participants who achieved loss of PTSD diagnosis/clinically meaningful response Each treatment arm is presented on its own row. There are also separate rows for studies with more than one measure, time point and analysis type or when there is more than one definition of diagnostic change or clinically meaningful change.

The Harms dataset includes information on serious adverse events and participant withdrawals from the studies due to adverse events. Adverse events are reported as the percent of participants within a treatment group that experienced an adverse event or who withdrew from the study. Detail on the specific adverse event or reason for withdrawal is provided when available. This dataset also reports on the percentage of patients who attempted or completed suicide (when available).
Values abstracted as "NA" or "NR" from the study are represented as null values/empty cells in this dataset.
Study level variables like military status and percent female are included for filtering purposes

Each study in the PTSD-Repository was coded for risk of bias (ROB) in specific domains as well as an overall risk of bias for the study. Detailed information about the specific coding strategy is available in Comparative Effectiveness Review [CER] No. 207, Psychological and Pharmacological Treatments for Adults with Posttraumatic Stress Disorder. (See our "Risk of Bias" data story.)
Most domains were rated as Yes (i.e., minimal risk of bias), No (i.e., high risk of bias) or Unclear (i.e., bias could not be determined). The overall study rating is based on the domains and is coded as low, medium or high risk of bias. The 4 domains that were included as components of the overall rating include: Selection bias--randomization adequate, allocation concealment adequate, groups similar at baseline and whether they used intention to treat analyses; Performance bias--care providers masked and patients masked; Detection bias--outcome assessors masked; Attrition bias--overall attrition less than or equal to 20% vs over 20%; differential attrition less than or equal to 15% vs over 15%.
Additional items assessed (but not considered as part of the overall rating) include: Reporting bias--all prespecified outcomes reported; Reporting bias--method for handling dropouts; Outcome measures equal valid and reliable; Study reports adequate treatment fidelity based on measurements by independent raters.

The U.S. Department of Veterans Affairs (VA) has established a long-term partnership to commission AHRQ to utilize its Evidence-based Practice Centers to develop update reviews to inform the VA’s PTSD-Repository – a publicly accessible clinical trials database maintained by the National Center for PTSD (NCPTSD).

The 2023 Report, Executive Summary and Evidence Tables (Appendix E, F, G1, & G2) are included in the downloadable .zip file. For more information, visit AHRQ's page: https://effectivehealthcare.ahrq.gov/products/ptsd-pharm-non-pharm-treatment/research

The U.S. Department of Veterans Affairs (VA) has established a long-term partnership to commission AHRQ to utilize its Evidence-based Practice Centers to develop update reviews to inform the VA’s PTSD-Repository – a publicly accessible clinical trials database maintained by the National Center for PTSD (NCPTSD).

The 2022 Report and Evidence Tables (Appendix F, G1, & G2-3) are included in the downloadable .zip file. For more information, visit AHRQ's page: https://effectivehealthcare.ahrq.gov/products/ptsd-pharm-treatment/research

Notes from Nick: Updated on 6/6/23 with Phase IV Data

The Other Outcomes dataset includes information on whether the trial includes measures of depression, anxiety, substance use, sleep, anger, quality of life and functioning. Results in this dataset are provided for each treatment arm. The name of the measure is included as well as the between-group effect sizes. Use this dataset to learn how about the effects of PTSD treatments on other outcomes.
Values abstracted as not applicable ("NA") or not reported ("NR") from the study are null values (empty cells).
Study level variables, like military status and percent female, are included for ease of filtering. These columns are not individual arm or arm comparison level data.

This dataset provides within-arm results for continuous measures. Included is information on score means and variance, and pre-post comparisons (pre-post score difference, statistical test p-value, and study-reported effect sizes). Where possible, the within-arm standardized effect size (analog of Cohen’s d) was calculated. For the calculated effect size, negative values indicate a lower score at follow-up compared to baseline, while positive values indicate a higher score at follow-up. Each treatment arm is presented on its own row. There are also separate rows for studies with more than one measure, time point and analysis type.

This dataset provides between-arm results for dichotomous outcomes: loss of diagnosis and clinically meaningful response. Included is information on how loss of diagnosis and clinically meaningful response were defined, p-value for statistical test, and study-reported effect sizes.

Each comparison is on a separate row, and pairwise as well as omnibus (multi-arm) comparisons are included. There are also separate rows for studies with more than one measure, time point and analysis type or when there is with more than one definition of diagnostic change or clinically meaningful change.

This table demonstrates how you might group together standardized treatments found in the PTSD-Repository to progressively move toward less specificity in classification. The example provided includes psychotherapy categories and is not exhaustive to all treatments found in the PTSD-Repository.